17 September 2020 
EMA/CHMP/267941/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Olumiant 
baricitinib 
On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Olumiant. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. 
The CHMP adopted a new indication as follows: 
Atopic Dermatitis: Olumiant is indicated for the treatment of moderate to severe atopic 
dermatitis in adult patients who are candidates for systemic therapy 
For information, the full indications for Olumiant will be as follows:2 
Rheumatoid Arthritis 
Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in 
adult patients who have responded inadequately to, or who are intolerant to one or more 
disease-modifying anti-rheumatic drugs. Olumiant may be used as monotherapy or in 
combination with methotrexate (see sections 4.4, 4.5 and 5.1 for available data on different 
combinations). 
Atopic Dermatitis 
Olumiant is indicated for the treatment of moderate to severe atopic dermatitis in 
adult patients who are candidates for systemic therapy. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
